Biosimilar biologics do not always reduce out-of-pocket costs
by Lori SolomonBiosimilar competition is not consistently associated with lower out-of-pocket (OOP) costs for commercially insured outpatients, according to a study published online March 29 inJ
Updated on: April 06,2024
0
Biosimilar biologics do not always reduce out-of-pocket costs
by Lori SolomonBiosimilar competition is not consistently associated with lower out-of-pocket (OOP) costs for commercially insured outpatients, according to a study published online March 29 inJ
Updated on:April 06,2024
0
